Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
ID06752239

Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in Nasopharyngeal Carcinoma (PROTECT-NPC): A Multicenter, Non-Inferiority, Open-Label, Randomized Controlled Phase III Clinical Trial

Led by Jiangxi Provincial Cancer Hospital · Updated on 2025-04-10

474

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting a multicenter, open-label, randomized Phase III clinical trial to compare two types of radiotherapy approaches for patients with nasopharyngeal carcinoma. The study focuses on evaluating how well modified delineation radiotherapy protects thyroid function compared to standard delineation radiotherapy. Important outcomes include the incidence of primary hypothyroidism, quality of life, and any adverse events experienced by participants. The trial involves two groups: one receiving modified delineation radiotherapy which adjusts the target area to spare the common carotid artery and reduce thyroid radiation exposure, and the other receiving standard delineation radiotherapy with the usual target boundaries. The modified approach changes the medial and anterior boundaries of the lymphatic drainage areas to potentially lessen thyroid damage. This study spans multiple centers and follows patients during their treatment. Participants will undergo regular follow-ups to monitor regional recurrence-free survival over three years, alongside assessments of overall survival, disease-free survival, and hypothyroidism-free survival. Quality of life will be evaluated at one, two, and three years after treatment. The study includes clinical evaluations, thyroid function tests, and safety monitoring to track outcomes and side effects. Total participant involvement may last several years to capture long-term effects and treatment impact.

CONDITIONS

Brief Title

Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 18 to 70 years
  • Pathologically confirmed nasopharyngeal carcinoma
  • No positive lymph nodes in unilateral or bilateral regions III and IVa
  • Clinical stage I-IVa (AJCC/UICC 8th edition) without distant metastasis
  • Normal thyroid function
  • ECOG performance status of 0-1
  • Treatment-nafve patients with no prior antitumor therapy
  • No contraindications to radiotherapy or chemotherapy
  • Adequate organ function as defined by blood counts and biochemical tests
  • Voluntary agreement to participate with informed consent and ability to comply with follow-up
Not Eligible

You will not qualify if you...

  • History of other malignant tumors (except certain skin cancers or cervical carcinoma in situ)
  • Previous radiotherapy excluding outside planned target areas
  • History of neck surgery
  • Severe comorbidities that pose risks or affect compliance, such as unstable heart disease, kidney disease, chronic hepatitis, uncontrolled diabetes, or psychiatric disorders
  • History of hyperthyroidism, hypothyroidism, or immune-related thyroid disorders
  • Family or social factors that may risk early study termination, patient safety, or data collection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - According to the radiotherapy schedule

Participants receive radiotherapy with either standard delineation or modified delineation to optimize thyroid function protection.

Follow-up

Duration - Up to 3 years

Participants are monitored for regional recurrence, survival outcomes, thyroid function, and overall health status after treatment.

Visits at 1 year, 2 years, and 3 years post-treatment

Trial Site Locations

Total: 1 location

1

Jiangxi Cancer Hospital

Nanchang, Jiangxi, China, 330029

Actively Recruiting

Loading map...

Research Team

X

Xiaochang Gong, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Multicenter Phase II Study of 18F-FDG PET/CT Guided Reduce...

Nasopharyngeal Carcinoma

Actively Recruiting

4 locations

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume ...

Nasopharyngeal Carcinoma

Actively Recruiting

15 locations

A Prospective Study to Assess Patient-Reported Cardiac Quali...

Hypertrophic Obstructive Cardiomyopathy

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here